JP5904953B2 - Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー - Google Patents

Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー Download PDF

Info

Publication number
JP5904953B2
JP5904953B2 JP2012556645A JP2012556645A JP5904953B2 JP 5904953 B2 JP5904953 B2 JP 5904953B2 JP 2012556645 A JP2012556645 A JP 2012556645A JP 2012556645 A JP2012556645 A JP 2012556645A JP 5904953 B2 JP5904953 B2 JP 5904953B2
Authority
JP
Japan
Prior art keywords
cells
als
level
cell
cd11b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012556645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522589A5 (enExample
JP2013522589A (ja
Inventor
ミカル・アイゼンバッハ−シュヴァルツ
エスター・ヨールズ
ハダス・ショリ
Original Assignee
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イエダ リサーチ アンド ディベロップメント カンパニー リミテッド, イエダ リサーチ アンド ディベロップメント カンパニー リミテッド filed Critical イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Publication of JP2013522589A publication Critical patent/JP2013522589A/ja
Publication of JP2013522589A5 publication Critical patent/JP2013522589A5/ja
Application granted granted Critical
Publication of JP5904953B2 publication Critical patent/JP5904953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
JP2012556645A 2010-03-10 2011-03-10 Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー Expired - Fee Related JP5904953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31233510P 2010-03-10 2010-03-10
US61/312,335 2010-03-10
PCT/IL2011/000227 WO2011111043A1 (en) 2010-03-10 2011-03-10 Cellular blood markers for early diagnosis of als and for als progression

Publications (3)

Publication Number Publication Date
JP2013522589A JP2013522589A (ja) 2013-06-13
JP2013522589A5 JP2013522589A5 (enExample) 2014-04-24
JP5904953B2 true JP5904953B2 (ja) 2016-04-20

Family

ID=43971347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012556645A Expired - Fee Related JP5904953B2 (ja) 2010-03-10 2011-03-10 Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー

Country Status (5)

Country Link
US (2) US20130230499A1 (enExample)
EP (1) EP2545381A1 (enExample)
JP (1) JP5904953B2 (enExample)
CA (1) CA2792471A1 (enExample)
WO (1) WO2011111043A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2819174T3 (es) * 2012-03-26 2021-04-15 Yeda Res & Dev Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer
EP3645040A4 (en) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
WO2019217916A1 (en) * 2018-05-10 2019-11-14 The Methodist Hospital Methods for prognosis and management of disease
DE102019121344A1 (de) * 2019-08-07 2021-02-11 ToposNomos Ltd. Verfahren und Durchflusszytometer zum Untersuchen einer menschlichen oder tierischen Zellprobe sowie Computerprogrammprodukt
CN118541152A (zh) * 2021-11-02 2024-08-23 特朗奎斯治疗股份有限公司 具有循环髓样细胞炎性表型的受试者的选择和治疗
WO2025058005A1 (ja) * 2023-09-15 2025-03-20 国立大学法人徳島大学 筋萎縮性側索硬化症（ａｌｓ）と関連するバイオマーカー

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426028A (en) * 1991-07-05 1995-06-20 Rush-Presbyterian-St. Lukes Medical Center Screening method for chronic immune dysfunction syndrome
US7410773B2 (en) * 1995-02-02 2008-08-12 Ghazi Jaswinder Dhoot Method of preparing an undifferentiated cell
DK1248643T3 (da) * 2000-01-20 2005-11-07 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
US20020081635A1 (en) * 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations
US20020155511A1 (en) * 2000-09-08 2002-10-24 Carolyn Horrocks Novel antibody compositions for the negative selection of specific rat leukocyte subsets
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
US7273888B2 (en) * 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
BRPI0616561A2 (pt) * 2005-09-12 2012-12-25 Council Scient Ind Res utilizaÇço dos derivados do composto de bipiridina "caerulomicina a" e seus equivalentes como agentes imunossupressores
KR20070113088A (ko) * 2006-05-24 2007-11-28 코아스템(주) 운동신경원질환 치료용 조성물 및 그 치료방법
US20120269774A1 (en) * 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
US10114012B2 (en) * 2008-10-31 2018-10-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and assays for detecting and quantifying pure subpopulations of white blood cells in immune system disorders
EP2416791A1 (en) * 2009-01-28 2012-02-15 Istituto Oncologico Veneto Myeloid-derived suppressor cells generated in vitro

Also Published As

Publication number Publication date
US20150209404A1 (en) 2015-07-30
CA2792471A1 (en) 2011-09-15
EP2545381A1 (en) 2013-01-16
JP2013522589A (ja) 2013-06-13
WO2011111043A1 (en) 2011-09-15
US20130230499A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
Larbi et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease
Spencer et al. Helper (CD4+) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle
JP5904953B2 (ja) Ａｌｓの早期診断およびａｌｓ進行のための細胞性血液マーカー
Richartz et al. Decline of immune responsiveness: a pathogenetic factor in Alzheimer’s disease?
ES2819174T3 (es) Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer
Wang et al. Nr4a1 plays a crucial modulatory role in Th1/Th17 cell responses and CNS autoimmunity
WO2015157117A2 (en) Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder
EP3320914A1 (en) T-helper 1 adjuvant for treating amyotrophic lateral sclerosis
JP2006512396A (ja) 免疫寛容を誘導および維持する方法
Hakimizadeh et al. Increased circulating levels of CXC chemokines is correlated with duration and complications of the disease in type-1 diabetes: a study on Iranian diabetic patients
Calvo et al. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity?
Seksenyan et al. Thymic involution, a co‐morbidity factor in amyotrophic lateral sclerosis
Panicucci et al. Muscle inflammatory pattern in alpha-and gamma-sarcoglycanopathies
Maurano et al. Intranasal administration of one alpha gliadin can downregulate the immune response to whole gliadin in mice
Jin et al. The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review
Osorio et al. CD8+-dependent CNS demyelination following ocular infection of mice with a recombinant HSV-1 expressing murine IL-2
Chou et al. CD4 T‐cell epitopes of human α B‐crystallin
Frisullo et al. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis
Martínez-Alcantar et al. Anterior chamber associated immune deviation to cytosolic neural antigens avoids self-reactivity after optic nerve injury and polarizes the retinal environment to an anti-inflammatory profile
Kamyan INVESTIGATING THE ROLE OF NATURAL KILLER (NK) CELLS IN OZANIMOD-MEDIATED REMISSION IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE) IN C57BL/6 MICE
EP3493835A1 (en) Method for ex vivo induction of suppressor lymphocytes using a solution of proteins from helminth parasites, lymphocytes produced by this method and uses thereof
Starosz et al. Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated Pediatric Graves’ Disease Patients. Genes 2021, 12, 164
Del Rosso et al. Health-Related Quality of Life and Sexual Health in Patients with Sjögren’s Syndrome and with Not-Sjögren’s Sicca Syndrome
Sartani et al. Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents
Richartz-Salzburger et al. Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer’s Disease?

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160315

R150 Certificate of patent or registration of utility model

Ref document number: 5904953

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees